New injection method without speculum for eye conditions
Part of Eyes & vision, Heart & circulation clinical trials.
This study compares two ways to keep the eye open during injections for conditions like wet macular degeneration. It tests a new method using a cotton-tipped applicator instead of a speculum to see if it is less painful and just as safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have one of these eye conditions: wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion
- You are scheduled to receive an eye injection of bevacizumab, aflibercept, or faricimab
- You do not have an active eye infection or inflammation
- You are not allergic to povidone-iodine, tetracaine, or levofloxacin
- You can cooperate with the injection procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
This trial tests whether specially trained nurses can safely give eye injections instead of doctors. It may make treatment quicker and easier for people who need regular injections for eye conditions.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.